We are developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential for clear differentiation compared to current CAR-T cell therapies. We seek to develop our product candidates by leveraging our relationships with clinicians and key opinion leaders in China, the United States and Europe. We partner with top-tier hospitals in China to streamline the safety and efficacy testing of our innovative pipeline product candidates in investigator-initiated trials that are conducted in accordance with international standards to support future global regulatory filings and clinical development. We have generated all our product candidates internally. Our most advanced product candidates are presented in the pipeline diagram below:
In addition to our lead product candidates, we have a broad portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, or PTCL, a subtype of NHL, and T cell lymphoblastic leukemia, or T-LBL.